The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites
Само за регистроване кориснике
2018
Аутори
Ignjatović, NenadPenov Gaši, Katarina
Ajduković, Jovana
Kojić, Vesna V.
Marković, Smilja
Uskoković, Dragan
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
An androstane (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (derivative A)) cancer inhibitor was successfully captured in a carrier made of nano-sized hydroxyapatite (HAp) coated with chitosan-PLGA polymer blends (Ch-PLGA). In our previous studies, we demonstrated that it was convenient to use spherical HAp/Ch-PLGA carriers as vehicles to target the lungs following intravenous administration. In this study, we used emulsification and subsequent freeze-drying to load the spherical HAp/Ch-PLGA carriers with varying contents of the derivative A, in order to examine the selective toxicity towards cancerous/healthy lung cells. The XRD and FT-IR techniques confirmed the drug loading process, and the content of the poorly water soluble derivative A was estimated directly via the DSC technique. The particles were spherical in shape with the d50 distribution varying between 167 and 231 nm, whereas the content of the derivative A ranged from 6.5 to 19.3 wt%. Cell-selective cytotoxicity was... examined simultaneously on two cell lines: human lung carcinoma (A549 ATCC CCL 185) and human lung fibroblasts (MRC-5 ATCC CCL 171). All particles exhibited nearly three times larger cytotoxicity towards cancer cells (A549) than towards healthy cells (MRC5), where the particles with the derivative A content of 6.5 wt% allowed for the viability of healthy cells >80%. Ninety-six hours after the treatment of cells with particles with different contents of derivative A (after incubation and recovery), recovery was faster in damaged healthy cells than in cancerous cells. © 2018 Elsevier B.V.
Кључне речи:
androstane / cell-selective cytotoxicity / hydroxyapatite / lung cancer / nanocarriersИзвор:
Materials Science and Engineering C, 2018, 89, 371-377Издавач:
- Elsevier
Финансирање / пројекти:
DOI: 10.1016/j.msec.2018.04.028
ISSN: 0928-4931
WoS: 000434239100039
Scopus: 2-s2.0-85045579234
Институција/група
Институт техничких наука САНУ / Institute of Technical Sciences of SASATY - JOUR AU - Ignjatović, Nenad AU - Penov Gaši, Katarina AU - Ajduković, Jovana AU - Kojić, Vesna V. AU - Marković, Smilja AU - Uskoković, Dragan PY - 2018 UR - https://dais.sanu.ac.rs/123456789/3699 AB - An androstane (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (derivative A)) cancer inhibitor was successfully captured in a carrier made of nano-sized hydroxyapatite (HAp) coated with chitosan-PLGA polymer blends (Ch-PLGA). In our previous studies, we demonstrated that it was convenient to use spherical HAp/Ch-PLGA carriers as vehicles to target the lungs following intravenous administration. In this study, we used emulsification and subsequent freeze-drying to load the spherical HAp/Ch-PLGA carriers with varying contents of the derivative A, in order to examine the selective toxicity towards cancerous/healthy lung cells. The XRD and FT-IR techniques confirmed the drug loading process, and the content of the poorly water soluble derivative A was estimated directly via the DSC technique. The particles were spherical in shape with the d50 distribution varying between 167 and 231 nm, whereas the content of the derivative A ranged from 6.5 to 19.3 wt%. Cell-selective cytotoxicity was examined simultaneously on two cell lines: human lung carcinoma (A549 ATCC CCL 185) and human lung fibroblasts (MRC-5 ATCC CCL 171). All particles exhibited nearly three times larger cytotoxicity towards cancer cells (A549) than towards healthy cells (MRC5), where the particles with the derivative A content of 6.5 wt% allowed for the viability of healthy cells >80%. Ninety-six hours after the treatment of cells with particles with different contents of derivative A (after incubation and recovery), recovery was faster in damaged healthy cells than in cancerous cells. © 2018 Elsevier B.V. PB - Elsevier T2 - Materials Science and Engineering C T1 - The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites SP - 371 EP - 377 VL - 89 DO - 10.1016/j.msec.2018.04.028 UR - https://hdl.handle.net/21.15107/rcub_dais_3699 ER -
@article{ author = "Ignjatović, Nenad and Penov Gaši, Katarina and Ajduković, Jovana and Kojić, Vesna V. and Marković, Smilja and Uskoković, Dragan", year = "2018", abstract = "An androstane (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (derivative A)) cancer inhibitor was successfully captured in a carrier made of nano-sized hydroxyapatite (HAp) coated with chitosan-PLGA polymer blends (Ch-PLGA). In our previous studies, we demonstrated that it was convenient to use spherical HAp/Ch-PLGA carriers as vehicles to target the lungs following intravenous administration. In this study, we used emulsification and subsequent freeze-drying to load the spherical HAp/Ch-PLGA carriers with varying contents of the derivative A, in order to examine the selective toxicity towards cancerous/healthy lung cells. The XRD and FT-IR techniques confirmed the drug loading process, and the content of the poorly water soluble derivative A was estimated directly via the DSC technique. The particles were spherical in shape with the d50 distribution varying between 167 and 231 nm, whereas the content of the derivative A ranged from 6.5 to 19.3 wt%. Cell-selective cytotoxicity was examined simultaneously on two cell lines: human lung carcinoma (A549 ATCC CCL 185) and human lung fibroblasts (MRC-5 ATCC CCL 171). All particles exhibited nearly three times larger cytotoxicity towards cancer cells (A549) than towards healthy cells (MRC5), where the particles with the derivative A content of 6.5 wt% allowed for the viability of healthy cells >80%. Ninety-six hours after the treatment of cells with particles with different contents of derivative A (after incubation and recovery), recovery was faster in damaged healthy cells than in cancerous cells. © 2018 Elsevier B.V.", publisher = "Elsevier", journal = "Materials Science and Engineering C", title = "The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites", pages = "371-377", volume = "89", doi = "10.1016/j.msec.2018.04.028", url = "https://hdl.handle.net/21.15107/rcub_dais_3699" }
Ignjatović, N., Penov Gaši, K., Ajduković, J., Kojić, V. V., Marković, S.,& Uskoković, D.. (2018). The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites. in Materials Science and Engineering C Elsevier., 89, 371-377. https://doi.org/10.1016/j.msec.2018.04.028 https://hdl.handle.net/21.15107/rcub_dais_3699
Ignjatović N, Penov Gaši K, Ajduković J, Kojić VV, Marković S, Uskoković D. The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites. in Materials Science and Engineering C. 2018;89:371-377. doi:10.1016/j.msec.2018.04.028 https://hdl.handle.net/21.15107/rcub_dais_3699 .
Ignjatović, Nenad, Penov Gaši, Katarina, Ajduković, Jovana, Kojić, Vesna V., Marković, Smilja, Uskoković, Dragan, "The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites" in Materials Science and Engineering C, 89 (2018):371-377, https://doi.org/10.1016/j.msec.2018.04.028 ., https://hdl.handle.net/21.15107/rcub_dais_3699 .